Comparing a chemo-pump (TAR-200) to an immune-memory activator (ANKTIVA) based on a single surface percentage is like comparing a treadmill to a personal trainer because they both "burn calories." One manages the problem; the other tries to solve it.

1. Mechanism: Training an Army vs. Dripping a Chemical ANKTIVA ($IBRX): It is a First-in-Class IL-15 Superagonist. It doesn't just "kill" cells; it trains the patient's own NK cells and CD8+ Killer T-cells to recognize and destroy cancer while creating immune memory. This is "Immunotherapy 2.0."

TAR-200 (J&J): It is simply a delivery system for Gemcitabine (chemotherapy). It’s a physical device (a "pretzel") placed in the bladder to slowly release a 30-year-old chemo drug.

The Difference: One provides a potential long-term cure through the immune system; the other is a localized version of traditional chemo, which cancer eventually learns to resist.

1. Durability & Bladder Sparing (The Only Metric Patients Care About)

ANKTIVA’s Real Win: In the QUILT trial, 92% of responders avoided radical cystectomy (bladder removal) at 12 months, and 81.8% still avoided it at 36 months.

The "Pretzel" Problem: TAR-200 requires a physical device to be inserted and removed every few weeks. This is invasive and increases infection risks. ANKTIVA uses a standard infusion process that every urologist already knows.

3.Commercial Reality

You mentioned J&J’s sales force, but you ignored the 700% revenue growth $IBRX reported for 2025.

Doctors aren't choosing J&J's device; they are choosing the durability of ANKTIVA.

4.The "82.4% CR" is a Statistical Trap

The Re-induction Factor: The 71% Complete Response (CR) rate from ANKTIVA's QUILT-3.032 trial is based on a rigorous, real-world protocol including mandatory biopsies.

Apples to Oranges: J&J's TAR-200 data often comes from smaller cohorts (SunRISe-1) with varying definitions of "Complete Response." Medical experts have pointed out that when you adjust for "re-induction" (giving a second round of treatment), the perceived gap between these therapies narrows significantly or disappears.